{"id":40848,"date":"2023-10-03T07:50:11","date_gmt":"2023-10-03T07:50:11","guid":{"rendered":"https:\/?p=40848"},"modified":"2023-10-03T07:50:11","modified_gmt":"2023-10-03T07:50:11","slug":"dhr-stock-forecast-16-drop-after-veralto-spinoff","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/dhr-stock-forecast-16-drop-after-veralto-spinoff\/","title":{"rendered":"DHR Stock Forecast: 16% Drop After Veralto Spinoff"},"content":{"rendered":"

\u00a0Shares of Danaher Corporation (DHR:NYE<\/a>) experienced a significant downturn, plunging by up to 16% during regular trading sessions yesterday. This abrupt decline followed the completion of Danaher’s spinoff of its Veralto unit. This offshoot had a substantial impact on the company’s stock performance. As a result, DHR stock hit a fresh 52-week low of $208.96 before ultimately closing the day down 2.8% at $213.74 on October 2, 2023. This article will highlight the adverse impact of this decline on the DHR stock forecast.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Danaher-Veralto Split:<\/span><\/h2>\n

Danaher Corporation, a renowned manufacturer and marketer of professional, medical, industrial, and commercial products and services, executed a strategic separation by spinning off its Veralto unit. Meanwhile, Veralto is primarily focused on the sectors of water quality and product identification.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Veralto’s Debut on NYSE and Share Distribution:<\/span><\/h3>\n

In the transaction, Danaher shareholders were provided with one share of Veralto for every three shares held in DHR stock on Saturday, September 30. As of yesterday, Veralto commenced trading on the New York Stock Exchange, operating under the ticker symbol VLTO. The distribution saw Danaher allocate approximately 246 million Veralto shares as part of this significant corporate restructuring.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

CEO’s Positive Outlook on Veralto Spin-off:<\/span><\/h3>\n

In a statement regarding the separation, Danaher’s President and CEO, Rainer Blair, expressed optimism, stating, “The successful spin-off of Veralto as an independent company creates exceptional opportunities for both Danaher and Veralto to better serve their customers, deliver on their respective strategic priorities, and create greater long-term shareholder value.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

DHR Investment Potential:<\/span><\/h2>\n

The Wall Street consensus sees Veralto’s separation as a boost for Danaher’s healthcare focus. Analysts are adjusting DHR stock price targets to match the new valuation post-spin-off.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

KeyBanc Analyst’s View:<\/span><\/h2>\n

KeyBanc<\/a> analyst Paul Knight adjusted the price target for DHR stock to better reflect the company’s revised value post-separation. Knight posits that the spin-off will unlock greater value for Danaher’s core business, which is now oriented towards being a pure-play life science firm. The analyst maintains an overweight rating on DHR, with a revised price target of $300, down from the earlier $325. This revised target implies a substantial 40.4% upside potential from the current trading levels.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

DHR Stock Forecast:<\/span><\/h2>\n

According to the DHR stock forecast from 15 analysts, the average analyst target price is $274.60. This projection underscores a notable opportunity for investors. Furthermore, DHR stock maintains an average analyst rating of Strong Buy. Stock Target Advisor’s analysts are Neutral, driven by 7 positive and 7 negative signals.<\/span><\/p>\n

<\/p>\n

\n
\n

DHR Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n